1. No category

CURRICULUM VITAE
NAME
Joel Byron Nelson, M.D.
WORK ADDRESS
University of Pittsburgh Physicians
Department of Urology
Shadyside Medical Center, Suite 209
5200 Centre Avenue
Pittsburgh, PA 15232
(412) 605-3013
(412) 605-3030
University of Pittsburgh School of Medicine
Department of Urology
700 Kaufmann Bldg.
3471 Fifth Ave.
Pittsburgh, PA 15213-3221
(412) 692-4093
Fax (410) 692-4101
EMAIL
[email protected]
EDUCATION
1980-1983
BA - Philosophy, The University of Pittsburgh, Pittsburgh, Pennsylvania
1984-1988
MD - Northwestern University Medical School, Chicago, Illinois
TRAINING
1988-1989
Intern in General Surgery, Northwestern University/McGaw Medical Center,
Chicago, Illinois
1989-1990
Resident in General Surgery, Northwestern University/McGaw Medical Center,
Chicago, Illinois
1990-1992
Resident in Urology, Northwestern University/McGaw Medical Center, Chicago,
Illinois
1992-1993
Leander Riba Research Fellow, Department of Urology, Northwestern
University/McGaw Medical Center, Chicago, Illinois
1
1993-1994
Chief Resident in Urology, Northwestern University/McGaw Medical Center,
Chicago, Illinois
EMPLOYMENT
1994-1999
Active, Full-time Staff in Urology, The Johns Hopkins Hospital, Baltimore, Maryland
1994-1996
Instructor in Urology, The Johns Hopkins University School of Medicine, Baltimore,
Maryland
1996-1999
Assistant Professor of Urology and Oncology, The Johns Hopkins University School
of Medicine, Baltimore, Maryland
1996-1999
Active, Full-time Staff in Urology, Johns Hopkins Bayview Medical Center,
Baltimore, Maryland
1996-1999
Director, Urologic Oncology, Johns Hopkins Bayview Medical Center, Baltimore,
Maryland
1999-
Frederic N. Schwentker Professor and Chairman, Department of Urology,
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
CERTIFICATION
1991-1996
License to practice medicine, State of Illinois # 036-084934
1995-1999
License to practice medicine, State of Maryland # D46103
1998-
Diplomate of the American Board of Urology
1999-
License to practice medicine, State of Pennsylvania #MD-069351-L
HONORS
1982
Omicron Delta Kappa National Honors Society, The University of Pittsburgh,
Pittsburgh, PA
1983
Graduate, Magna Cum Laude, The University of Pittsburgh, Pittsburgh, PA
1987
The George Dennis Award, Outstanding performance in the required clerkships,
Northwestern University Medical School, Chicago, Illinois
1987
Alpha Omega Alpha, Northwestern University Medical School, Chicago, Illinois
2
1991
First Prize, Resident Paper Competition, Chicago Committee on Trauma of the
American College of Surgeons, Chicago, Illinois
1991
Second Prize, Irving Shapiro X-Ray Conference, Chicago Urological Society,
Chicago, Illinois
1992
Dr. Leander W. Riba Urology Award, Outstanding performance in clinical urology,
Northwestern University/McGaw Medical Center, Chicago, Illinois
1992
Third Prize, Irving Shapiro X-Ray Conference, Chicago Urological Society, Chicago,
Illinois
1993
First Prize, Irving Shapiro X-Ray Conference, Chicago Urological Society, Chicago,
Illinois
1993
Recipient, Traveling Fellowship Essay Award, North Central Section, American
Urological Association, 67th Annual Meeting, Milwaukee, Wisconsin
1994
First Prize, Basic Science Category, Charles B. Huggins, M.D. Resident Essay
Contest, Chicago Urological Society, Chicago, Illinois
1994-1996
Dornier Scholar, American Foundation for Urologic Disease
1995
First Prize, Annual Essay Contest, Society for Basic Urologic Research, Fall
Symposium, Chapel Hill, North Carolina
1995
CaP CURE Research Award
1996
Third Prize, Research Category, AUA/Circon ACMI Prize Essay Contest, American
Urological Association, 91st Annual Meeting, Orlando Florida
1996
CaP CURE Research Award
1997
Pfizer Scholars in Urology
1997
CaP CURE Research Award
1998
CaP CURE Research Award
1999
SBUR/Merck Young Investigator Award
1999
CaP CURE Research Award
2000
Fellow, AUA/EUA Academic Fellowship Program 2000 European Exchange
3
2001
Listed in the National Registry of Who's Who, Published in the 2001 Edition
2001
America's Top Doctors
2002
America's Top Doctors
2003
Resident Teaching Award, Department of Urology, University of Pittsburgh
2003
America's Top Doctors
2003
Donald S. Coffey - CaP CURE Physician-Scientist Award
2004
America's Top Doctors
2004
Listed in the National Registry of Who's Who in Medicine and Healthcare
2005
Listed in National Registry of Who's Who, Executives and Professionals
2005
Pittsburgh Business Times, Finalist, Health Care Hero Award
2005
Pittsburgh Magazine, Best Doctors in Pittsburgh
2005
Elected to Membership, American Association of Genitourinary Surgeons
EDITORIAL CONSULTANT
1) Board of Consulting Editors, Urology, 1999.
2) Consulting Editor, Prostate Cancer and Prostatic Diseases, 2000.
3) Editorial Board, The Prostate, 2000
4) Editorial Board, Section of Investigative Urology, BJU International, 2004
AD HOC REVIEWER
1992- The Journal of Urology
1995- Nature Medicine
1996- Cancer Research
1996- Molecular Pharmacology
4
1997- Clinical Therapeutics
1997- Nature
1998- Urology
1998- Clinical Cancer Research
1998- The New England Journal of Medicine
1998- The Prostate
1999- Oncogene
1999- The Journal of Clinical Investigation
1999- Nature Cell Biology
1999- The Journal of Laboratory and Clinical Medicine
2000- FASEB Journal
2000- Journal of the National Cancer Institute
2000- International Journal of Cancer
2000- Hormone and Metabolic Research
2000- The American Journal of Pathology
2000- Prostate Cancer and Prostatic Diseases
2001- Analytical Pharmacology
2002- Experimental Cell Research
2002- British Journal of Cancer
2002- Trends in Endocrinology and Metabolism
2003- Journal of Clinical Oncology
2003- BJU International
2004- Clinical Prostate Cancer
5
2004- Oncology
2004- Expert Opinion on Investigational Drugs
SCIENTIFIC ADVISORY
1997- Molecular Therapeutics Venture, Abbott Laboratories
1997- National Kidney Foundation of Maryland
1998- The American Red Cross, Fibrin Sealant Bandage Clinical Trial
1999- Global Experts, Yamanouchi Pharmaceutical Co., Ltd.
2000- Consultants in Hormone Refractory Prostate Cancer, Aventis Pharmaceutical
2000- Prostate Cancer Advisory Board, Amgen and PRAECIS
2002- Astra-Zeneca
2002- Atrasentan Urological Oncology Advisory Board, Abbott Laboratories
2004- Corixa: P501 Advisory
2004- Novacea Advisory Board
MEMBERSHIPS
1993- American Urological Association
1997- American Association for Cancer Research
1997- American Association for the Advancement of Science
1997- Eastern Cooperative Oncology Group
1997- American Medical Association
1997- American Association for the Advancement of Science
1998- American Society of Clinical Oncology
1998- Society for Basic Urological Research
6
2000- Pennsylvania Medical Society
2000- Allegheny County Medical Society
2004- Buffalo Urological Society (Honorary Membership)
2005- American Association of Genitourinary Surgeons
GRANTS, CONTRACTS AND AWARDS
1. American Foundation for Urologic Diseases Award: "GM-CSF Therapy of Prostate Cancer in
the Dunning Model", Principal Investigator, Award 1994-1996: $22,000/year.
2. N.I.H. National Research Service Award: 2T32DK07552, Award 1994-1996: $63,100.
3. N.I.H. Special Program of Research Excellence in Prostate Cancer, Co-Investigator, Award 19951998: $124,000/year.
4. CaP CURE Research Award: "Endothelin-1: A Therapeutic Target for Metastatic Prostate
Cancer", Principal Investigator, Award 1995-1996: $100,000.
5. Abbott Laboratories Unrestricted Fellowship: Principal Investigator, Award 1996-1997: $113,000
TDC.
6. CaP CURE Research Award: “Targeting the Endothelin Axis in the Treatment of Metastatic
Prostate Cancer”, Principal Investigator, Award 1996-1997: $100,000.
7. Johns Hopkins Bayview Physicians, P.A.: “Targeting Endothelin Mediated Tumor Blood Flow in
the Treatment of Metastatic Prostate Cancer”, Principal Investigator, Award 1997: $5,000.
8. Abbott Laboratories Research Contract: “Inhibition of New Bone Formation by Endothelin
Receptor Antagonists”, Principal Investigator: $25,582.
9. National Cancer Institute: “The Role of the Endothelin B Receptor in Prostate Cancer”
CA74090-01, Principal Investigator, Award 1997-2002: $435,710 TDC.
10. American Foundation for Urologic Diseases Award: “Inhibition of New Bone Formation by
Endothelin Receptor Antagonists”, Preceptor/Mentor, Award Summer 1997: $2,000.
11. National Cancer Institute: “Functional Imaging of the Metastatic Phenotype” CA73850-01, CoInvestigator, Award 1997-2001: $985,566 TDC.
12. Pfizers Scholars in Urology Grant: Awardee, 1997: $2,000.
7
13. CaP CURE Research Award: “The Endothelin Axis: Focusing Therapy for Metastatic Prostate
Cancer”, Principal Investigator, Award 1997-1998: $100,000.
14. Robert and Barbara Knollenberg, Awardee 1997: $250,000.
15. Johns Hopkins Bayview Physicians, P.A.: “Targeting Endothelin Axis in Androgen Independent
Prostate Cancer”, Principal Investigator, Award 1998: $4,000.
16. Abbott Laboratories Unrestricted Travel Grant: Awardee, 1998: $1,000.
17. U.S. Army Medical Research and Materiel Command (USAMRMC) Prostate Cancer Research
Program (PCRP), Minority Population Focused Training (MPFT) Grant: “Amplification of the
Endothelin A Receptor Gene: A Potential Molecular Biomarker of Aggressive Prostate Cancer in
African Americans” MP980001, Principal Investigator, Award 1998: $49,279.
18. Robert and Barbara Knollenberg, Awardee 1998: $50,000.
19. AMEDIC AB Sweden, Research Contract: Ex vivo Study of the Biopince Needle and Prostate
Cancer Diagnosis”, Principal Investigator, 1998-99: $10,000.00.
20. Revival, Doctor Formulated Soy Protein: A Single Center Trial to Evaluate the Effects of
Revival Doctor-Formulated Soy Protein on Various Grades of Cancerous Prostate Cells, Prostate
Specific Antigen (PSA) Levels, and Testosterone Levels, Principal Investigator, 1998-99, $16,480.00.
21. CaP CURE Research Award: “Endothelin Axis Blockade: Maximizing Efficacy in the Treatment
of Advanced Prostate Cancer ”, Principal Investigator, Award 1998-1999: $100,000.
22. Johns Hopkins Bayview Physicians, P.A.: “Role of Nanobacteria in Urinary Calculi”, CoInvestigator, Award 1999: $5,000.
23. Mellam Family Foundation, Awardee 1999: $35,000.
24. A Phase III, Open-Label, Multi-Center Study of the Efficacy and Safety of Leuprolide Acetate
for Depot Suspension 7.5 mg (30 day) Formulation in Patients with Advanced Prostate Cancer,
Principal Investigator, $14,847.
25. Randomized Prospective Study of Adjuvant Androgen Ablation in Radical Prostatectomy
Patients at High-Risk for Disease Recurrence, Principal Investigator, $87,935.
26. Abbott Laboratories Unrestricted Travel Grant: Awardee, 1999: $1,000.
27. Bristol-Myers Squibb Company Unrestricted Grant: Awardee, 1999: $5,000.
28. Yamanouchi Corporation Contract: “Study of the Yamanouchi Endothelin Receptor Antagonist
in an Osteoblastic Tumor Model, Principal Investigator, 1999: $52,354
8
29. U.S. Army Medical Research and Materiel Command (USAMRMC) Prostate Cancer Research
Program (PCRP) Grant: “Fatty Acid Synthesis and Prostate Cancer: Hormonal Regulation and AntiMetabolite Targeting of an Acquired Function in Neoplasia”, Co-Investigator, 1999-2002, $375,000
TDC.
30. Mellam Family Foundation, Awardee 2000: $35,000
31. CaP CURE Research Award: “Fatty Acid Synthase: A Novel Target for Advanced Prostate
Cancer Therapy and Imaging”, Principal Investigator, Award 1999-2000: $100,000
32. Mellam Family Foundation, Awardee 2001-2003: $105,000
33. Astra-Zeneca Oncology: Unrestricted grant, Principal Investigator, Award 2002-2004: $350,000
TDC.
34. National Cancer Institute N01-CN-75018: "A Phase II Randomized, Controlled Clinical Trial of
the Antiestrogen GTx-006 in Subjects with Prostate Cancer, Principal Investigator, 2002, $417,000
TDC.
35. Abbott Laboratories: Unrestricted grant, Principal Investigator, Award 2003-2004: $200,000
TDC
PATENTS
1. Provisional Patent No. 60/513,729 "Endothelin Axis and the Action of Dendritic Cells" Georgi
Guruli, Beth R. Pflug, Michael R. Shurin, Joel B. Nelson.
CLINICAL TRIALS
1. “A phase I, open label, escalating dose study of the safety and pharmacokinetics of ABT 627 in
patients with refractory adenocarcinoma.” Co-investigator.
2. “Extension of the multiple dose study of the safety and pharmacokinetics of ABT-627 in patients
with refractory adenocarcinoma.” Co-investigator.
3. “Phase II, double-blind comparison of the safety and efficacy of ABT-627 versus placebo in
subjects with symptomatic hormone refractory prostate cancer.” Co-investigator.
4. “A phase II, double-blind comparison of the safety and efficacy of ABT-627 versus placebo in
subjects with asymptomatic hormone refractory prostatic cancer.” Co-investigator.
5. “Extension study of the phase II, double-blind comparison of the safety and efficacy of ABT-627
9
in subjects with hormone refractory prostate cancer.” Co-investigator.
6. “Molecular Diagnosis of Bladder Cancer” Co-Investigator.
7. “A Single Center Trial to Evaluate the Effects of Revival Doctor-Formulated Soy Protein on
Various Grades of Cancerous Prostate Cells, Prostate Specific Antigen (PSA) Levels, and
Testosterone Levels.” Principal Investigator.
8. “A Phase III, Open-Label, Multi-Center Study of the Efficacy and Safety of Leuprolide Acetate
for Depot Suspension 7.5 mg (30 day) Formulation in Patients with Advanced Prostate Cancer.”
Principal Investigator.
9. “Randomized Prospective Study of Adjuvant Androgen Ablation in Radical Prostatectomy
Patients at High-Risk for Disease Recurrence.” Principal Investigator.
10. "Detection of Recurrent Bladder Cancer by Microsatellite Analysis of Urinary Sediment."
Principal Investigator.
11. "Sample Acquisition for BLCA-4 Testing in the Diagnosis of Bladder Cancer." Co-investigator.
12. "Randomized Prospective Study of Adjuvant Androgen Ablation in Radical Prostatectomy
Patients at High Risk for Disease Recurrence." Co-Investigator.
13. "Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial
Bladder Cancer." Co-Investigator.
14. “A Phase II, Open-Label, Multi-Center Study of the Efficacy and Safety of Oakwood
Laboratories' Leuprolide Acetate for Depot Suspension 22.5 mg in Patients with Advanced Prostate
Cancer.” Co-Investigator.
15. "A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy
of 10 mg Atrasentan in Men with Metastatic, Hormone-Refractory Prostate Cancer." Principal
Investigator.
16. " A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy
of 10 mg Atrasentan in Men with Non-Metastatic, Hormone-Refractory Prostate Cancer." Principal
Investigator.
17. "A Phase III Extension Study to Evaluate the Safety of 10 mg Atrasentan in Men with
Hormone-Refractory Prostate Cancer." Principal Investigator.
18. "A Phase II Randomized, Controlled Clinical Trial of the Antiestrogen GTx-006 in Subjects with
Prostate Cancer." Principal Investigator
19. "A Phase II Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men with
Hormone Naïve Prostate Cancer that are Exhibiting Early Signs of Biochemical Failure." Principal
10
Investigator.
20. "A Phase II randomized, controlled clinical trial of the antiestrogen GTx-006 in subjects with
prostate cancer." Principal Investigator.
21. "Hormones and Biomarkers of Prostate Cancer Risk." Co-Investigator.
22. "A Randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety
of dutasteride 0.5 mg administered orally once daily for four years to reduce the risk of biopsydetectable prostate cancer." Principal Investigator.
23. "Selenium and Vitamin E Cancer Prevention Trial (SELECT)." Co-investigator.
24. "A multicenter, Phase IIb, four arm, dose finding, randomized, placebo-controlled study to
determine the long term prostate cancer chemoprevention efficacy and safety of 20 mg, 40 mg & 60
mg daily of GTx-006 in men with high grade prostate intraepithelial neoplasia." Co-investigator.
SCIENTIFIC PEER REVIEW
1. National Kidney Foundation of Maryland, Inc., 1997 Research Grants, May 21, 1997.
2. U.S. Army Medical Research and Materiel Command, 1997 Prostate Cancer Research Program,
Panel: Cell Biology-2, January 11-13, 1998.
3. National Kidney Foundation of Maryland, Inc., 1998 Research Grants, May 27, 1998.
4. U.S. Army Medical Research and Materiel Command, 1999 Prostate Cancer Research Program,
Panel: Cell Biology-2, May 12-14, 1999.
5. National Kidney Foundation of Maryland, Inc., 1999 Research Grants, May 26, 1999.
6. Department of Veterans Affairs, 2001 Fall Research Grants, External Reviewer
7. CaP CURE, 2002 Competitive Research Awards, Reviewer, December 5-6, 2002
ADMINISTRATION
1. Member, Cancer Committee, Johns Hopkins Bayview Medical Center, 1999.
2. Member, Ambulatory Care Committee, Johns Hopkins Bayview Medical Center, 1999.
3. Member, Medical School Council, Johns Hopkins University School of Medicine, 1999.
4. Co-Director, Pittsburgh Urological Cancer Program, Pittsburgh Cancer Institute, 1999-present.
11
5. Member, Council of Clinical Chairs, University of Pittsburgh School of Medicine. 1999-present.
6. Member, Executive Committee, University of Pittsburgh School of Medicine. 1999-present.
7. Program Director, Urology Residency Program, University of Pittsburgh School of Medicine,
1999-present
8. Member, UPP Finance Committee, University of Pittsburgh School of Medicine, 2000-2001.
9. Chairman, UPP Finance Committee, University of Pittsburgh School of Medicine, 2001-present.
10. Member, Joint Appointment Committee, University of Pittsburgh School of Medicine, 2001present.
11. Member, Education Committee, American Urological Association, 2001-present.
12. Member, Search Committee for Chairman, Department of Ophthalmology, University of
Pittsburgh School of Medicine, 2002.
13. Treasurer, University of Pittsburgh Physicians, 2002-present.
14. Member, Nominating Committee, Northeastern Section, AUA, 2002-2004.
15. Member, Representing Departments at Large, Executive Committee, University of Pittsburgh
Physicians, 2003-2005.
16. Chairman, Search Committee for Chairman, Department of Obstetrics and Gynecology,
University of Pittsburgh School of Medicine, 2003.
17. Division Chief, Urology, UPMC Shadyside Hospital.
18. Board of Directors, Pennsylvania Representative, Northeastern Section of the American
Urological Association, 2003-2005.
19. Member, Cancer Epidemiology Search Committee, University of Pittsburgh, School of Public
Health
20. Member, Search Committee for Chairman, Department of Otolaryngology, University of
Pittsburgh School of Medicine, 2004-2005
21. Member, Representing Surgical Departments, Executive Committee, University of Pittsburgh
Physicians, 2005-2007
22. Chair, Council of Clinical Chairs, University of Pittsburgh School of Medicine/University of
Pittsburgh Physicians, 2005-2007
12
INVITED LECTURES
1. "Endothelin and Advanced Prostate Cancer", Northwestern University Medical School,
Department of Urology, Chicago, IL March 1, 1995
2. "Endothelin and Advanced Prostate Cancer", Georgetown University School of Medicine,
Washington DC, May 18, 1995
3. "Endothelin and Advanced Prostate Cancer", Abbott Laboratories, Pharmaceutical Products
Division, Abbott Park, IL, May 22, 1995
4. "The Molecular Pathophysiology of Endothelin-1 in Prostate Cancer", Abbott Laboratories,
Pharmaceutical Products Division, Abbott Park, IL, July 24, 1995
5. "Endothelin Production and Decreased ETB Receptor Expression in Advanced Prostate Cancer",
Society for Basic Urologic Research, Fall Symposium, Chapel Hill, North Carolina, December 10,
1995
6. “Controversies in Prostate Cancer”, Department of Nephrology, Johns Hopkins Bayview Medical
Center, Baltimore, MD, June 11, 1996
7. “The Endothelin Axis in Prostate Cancer”, Eastern Virginia Medical College, Norfolk, VA,
August 19, 1996
8. “Endothelin-1: A Therapeutic Target for Metastatic Prostate Cancer”, CaP CURE, Third Annual
Scientific Retreat, Incline Village, NV, September 6, 1996
9. “Prostate Cancer Bone Metastasis”, University of Virginia, Charlottesville, VA, October 28, 1996
10. “Endothelin and Prostate Cancer”, Grand Rounds, Department of Surgery, Johns Hopkins
University School of Medicine, Baltimore, MD, February 8, 1997.
11. “Endothelin-1: A Therapeutic Target for Metastatic Prostate Cancer”, CaP CURE, Fourth
Annual Scientific Retreat, Incline Village, NV, September 4, 1997
12. “Endothelins: Basic Biology”, Molecular Therapeutics Venture, Abbott Laboratories, Abbott
Park, IL, September 19, 1997
13. “Endothelin and Prostate Cancer”, Bristol Myers Squibb, Pharmaceutical Research Institute,
Princeton, NJ, November 11, 1997
14. “Benign Prostatic Hyperplasia”, Pratt Pharmaceuticals, Baltimore, MD, December 17, 1997
15. “Radical Retropubic Prostatectomy”, U.S. Naval Academy Class of 1946, Arlington, VA, January
13
16, 1998
16. “Endothelins”, 1998 International Symposium on Biology of Prostate Growth, National
Institutes of Health, Bethesda, MD, March 17, 1998
17. “The Role of Endothelin in the Biology of Advanced Prostate Cancer”,The Committee on
Cancer Biology, The Cancer Research Center, Department of Urology, University of Chicago,
Chicago, IL, May 12, 1998
18. “The Role of Endothelin in Prostate Cancer”, Division of Nephrology, The Mount Sinai
Medical Center, New York, NY, May 18, 1998
19. “The Inhibition of Novel Non Androgen-Independent Pathways of Prostate Cancer
Progression”, Management and Treatment of Advanced Carcinoma of the Prostate, 93rd Annual
American Urological Association Meeting, San Diego June 2, 1998
20. “Endothelin and Prostate Cancer: From Bench to Bedside”, Johns Hopkins Oncology Center
Research Retreat, Baltimore, MD, June 19, 1998
21. “Technique and Results of Radical Prostatectomy”, American College of Osteopathic Surgeons,
Urologic Discipline Mid-Year Meeting, Baltimore, MD, July 31, 1998
22. “The Endothelin Axis: Focusing Therapy for Metastatic Prostate Cancer”, CaP CURE, Fifth
Annual Scientific Retreat, Incline Village, NV, September 12, 1998
23. “Urology News: Impotence, Prostatism”, 26th Annual Current Topics in Geriatrics, Baltimore,
MD, October 9, 1998
24. “Endothelin and Prostate Cancer”, Seminar, NMR Division, Department of Radiology, Johns
Hopkins University Medical School, Baltimore, MD, November 11, 1998
25. “BPH Management Program for Primary Care Physicians”, Baltimore, MD, U.S.
Pharmaceuticals, Pfizer Inc., November 18, 1998
26. “Endothelin-receptor antagonist, ABT-627, for prostate cancer: initial trial results”, New
Research Approaches in the Prevention and Cure of Prostate Cancer, AACR, Indian Wells, CA,
December 6, 1998
27. “Endothelin Receptor Antagonists in the Treatment of Prostate Cancer”, Bristol Myers Squibb,
Pharmaceutical Research Institute, Princeton, NJ, January 27, 1999
28. “Prostate Update”, The Pennsylvania Hospital, Philadelphia, PA, February 9, 1999
29. “Endothelin Antagonists in Clinical Prostate Cancer”, The 7th Annual Genitourinary Oncology
Conference, The University of Texas M. D. Anderson Cancer Center, Houston, TX, February 19,
1999
14
30. “Current Trends in the Management of Benign Prostatic Hyperplasia”, Baltimore, MD, U.S.
Pharmaceuticals, Pfizer Inc., February 23, 1999
31. “Current Trends in the Management of Benign Prostatic Hyperplasia”, Pittsburgh, PA, U.S.
Pharmaceuticals, Pfizer Inc., March 1, 1999
32. “New Treatment Modalities in Prostate Cancer, with Emphasis on Endothelin Receptor
Antagonists”, 3rd Round Table Meeting, Facts & Future Lines of Research in LUTS and Prostate
Cancer, Yamanouchi Pharmaceutical Co., Barbados, March 19, 1999
33. “Prostate Cancer: Decision Analysis and Surgical Treatment”, Diagnosis and Treatment of
Neoplastic Disorders, Johns Hopkins Oncology Center’s 25th Annual Symposium, Baltimore, MD,
March 25, 1999
34. “New Minimally Invasive Procedures for Benign Prostatic Hyperplasia”, 3rd Annual Men’s
Health 1999, Johns Hopkins Medical Institutions, Baltimore, MD, April 9, 1999
35. “Fatty Acid Synthase in Prostate Cancer: Preliminary Data” FAS Working Group, Johns
Hopkins University School of Medicine, Baltimore, MD, April 9, 1999
36. “Endothelin Antagonists in Prostate Cancer”, Merck Research Laboratories, Rahway, NJ, July
26, 1999
37. “Treatment of Locally Advanced Renal Cell Carcinoma”, Urology Postgraduate Conference,
Innovations in Urology, University of Iowa College of Medicine, Iowa City, Iowa, October 8,
1999
38. “Prostate Cancer: Diagnostic and Treatment Innovations”, Urology Postgraduate Conference,
Innovations in Urology, University of Iowa College of Medicine, Iowa City, Iowa, October 8,
1999
39. “Endothelins and Potential Role of ET Receptor Antagonists”, Yamanouchi Global Expert
Meeting, Dulles, VA, October 12, 1999
40. “The Endothelin Axis: Focusing Therapy for Metastatic Prostate Cancer”, CaP CURE, Sixth
Annual Scientific Retreat, Incline Village, NV, October 15, 1999
41. “Endothelin Receptor Antagonism in Prostate Cancer”, 8th Prouts Neck Meeting on Prostate
Cancer, New Visions on Prostate Cancer from Young Investigators, Prout's Neck, ME,
October 23, 1999
42. “Current Issues and Treatment of Prostate Cancer”, Rhone-Poulenc Rorer, November 4, 1999
43. “New Approaches to Prostate Cancer”, UPCI Clinical Oncology, Pittsburgh, PA, November 8,
1999
15
44. “Anti Angiogenesis Agents”, Advances in the Diagnosis and Treatment of Prostate Cancer,
Seattle, WA, November 20, 1999
45. “New Treatments for Prostate Cancer”, Westmoreland Regional Hospital, Greensburg, PA,
November 23, 1999
46. “What’s New in Prostate Cancer”, Pittsburgh Urological Association, Pittsburgh, PA,
December 13, 1999
47. “Prostate Cancer: Days in a Life”, UPMC Passavant, Pittsburgh, PA, Continuing Medical
Education Program, January 11, 2000
48. “Prostate Cancer: What you need to know”, UPMC Braddock, Prostate Cancer Awareness
Program, Pittsburgh, PA, January 12, 2000
49. “Prostate Cancer: Days in a Life”, UPMC Shadyside, Tumor Board, Pittsburgh, PA, March 1,
2000
50. “New Insights in the Management of Prostate Cancer”, Bristol-Myers Squibb
Oncology/Carnegie Museum, Pittsburgh, PA, March 16, 2000
51. “Prostate Cancer: What you need to know”, UPMC Beaver Valley/American Serbian Club,
Alliquipa, PA, March 22, 2000
52. "Take the First Step: What You Need to Know About Prostate Cancer", Public Education
Program, Sheraton Station Square Hotel, Pittsburgh, PA, June 17, 2000
53. "A Multi-Modality Approach to Treating Hormone Refractory Prostate Cancer",
Aventis/Chicago, Chicago, IL, June 24, 2000.
54. "Controversies in the Laparoscopic Management of Urologic Malignancies", Jackson Hole
Urology Conference, Jackson, WY, July 30, 2000
55. "Novel Treatments for Advanced Prostate Cancer: Smart Viruses, Snake Venoms, and
Megavitamins", Jackson Hole Urology Conference, Jackson, WY, July 30, 2000
56. "Hormone Therapy for Prostate Cancer: Who? When? How?", Jackson Hole Urology
Conference, Jackson, WY, August 1, 2000
57. The Menu of Localized Prostate Cancer Treatments: Old Favorites and Blue Plate Specials",
Jackson Hole Urology Conference, Jackson, WY, August 1, 2000
58. "Laparoscopic RPLND for Testes Cancer: Is Plucking Enough?", Jackson Hole Urology
Conference, Jackson, WY, August 2, 2000
16
59. The Basic Science of Prostate Cancer: What's Hot and What's Not", Jackson Hole Urology
Conference, Jackson, WY, August 3, 2000
60. "Atrasentan (ABT-627) prolongs time to clinical progression in men with hormone refractory
prostate cancer", CaP CURE, 7th Annual Retreat, Incline Village, NV, September 22, 2000
61. "Insights into Management of Prostate Cancer", Bristol-Myers Squibb Oncology, Tarrytown
NY, September 27, 2000
62. "Role of endothelin and endothelin receptor antagonists in prostate cancer", Department of
Pharmacology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, October 6, 2000
63. "Prostate cancer update", Third annual USO Fall Conference, Pittsburgh, PA, October 21,
2000.
64. ""His" and "Her" Cancers and Their Treatment", University of Pittsburgh, Mini-Medical School,
Pittsburgh, PA, October 24, 2000
65. "Diseases of the Prostate: BPH and Cancer", Update in Internal Medicine: 2000, Pittsburgh, PA,
October 27, 2000
66. "Prostate Cancer Update", Medical Grand Rounds, UPMC-St. Margaret Hospital, Pittsburgh,
PA, November 2, 2000
67. "Endothelin Receptor Antagonist Trials", NCI/Society of Urological Oncology Meeting,
National Institutes of Health, Betheseda, MD, December 3, 2000
68. "Prostate Cancer Update", Medical Grand Rounds, UPMC-McKeesport, McKeesport, PA,
December 5, 2000
69. "The Menu of Localized Prostate Cancer Treatments: Old Favorites and Blue Plate Specials",
Jackson Hole Urology Conference, Jackson, WY, January 28, 2001
70. "Controversies in the Laparoscopic Management of Urologic Malignancies", Jackson Hole
Urology Conference, Jackson, WY, January 29, 2001
71. "Novel Treatments for Advanced Prostate Cancer: Smart Viruses, Snake Venoms, and
Megavitamins", Jackson Hole Urology Conference, Jackson, WY, January 29, 2001
72. "Hormone Therapy for Prostate Cancer: Who? When? How?", Jackson Hole Urology
Conference, Jackson, WY, January 30, 2001
73. "The Basic Science of Prostate Cancer: What's Hot and What's Not", Jackson Hole Urology
Conference, Jackson, WY, February 1, 2001
74. “Advances in the Treatment of Prostate Cancer”, Aventis Oncology, Pittsburgh, PA, March 2,
17
2001
75. "Laparoscopy will replace open radical prostatectomy: CON", Issues and Controversies in
Prostate Care, Whistler, British Columbia, March 16, 2001
76. "Endothelin Receptor Blockers", Issues and Controversies in Prostate Care, Whistler, British
Columbia, Canada, March 17, 2001
77. "State of the Art Lecture--Prostate Cancer", Czech Winter Symposium, Spindleruv Mlyn, Czech
Republic, March 19, 2001
78. "Endothelin-A Receptor Antagonists and the Treatment of Prostate Cancer", The Endothelin
Axis: A New Cancer Therapeutic Target, ASCO 2001, San Francisco, May 11, 2001
79. “Prostate/PSA evaluation in Primary Care”, 28th Annual Refresher Course in Family Practice,
Pittsburgh June 15, 2001
80. “Urological Oncology”, 4th Annual AUA Highlights Course, Washington University of St.
Louis, St. Louis, July 14, 2001
81. "Hormonal Treatment of Prostate Cancer" US Too, Pittsburgh, August 15, 2001
81. "Bench to Bedside: Endothelin receptor antagonists in the treatment of prostate cancer"
Inaugural Lecture, Frederic N. Schwentker Chair in Urological Surgery, University of Pittsburgh,
October 16, 2001
82. "Diseases of the prostate: prostatitis, cancer, clinical utility of PSA" Update in Internal Medicine:
2001, Pittsburgh, November 16, 2001
83. "Atrasentan: a new non-chemotherapeutic agent in prostate cancer", Prostate Cancer Meeting,
EORTC/EAU, Amsterdam, January 17, 2002
84. "GU oncology highlights from the 2001 American Urological Association Meeting",
Westmoreland Regional Hospital, Greensburg, PA, March 5, 2002
85. Philadelphia Urologic Society, Residents' Night Competition, Judge, Philadelphia, PA, March 25,
2002
86. "What is the role of endothelin in prostate cancer?", Astra Zeneca Oncology, San Francisco, CA,
April 10, 2002
87. "Endothelin-1 and Endothelin Receptor Antagonists: Preclinical Results", Targeted Therapies in
the Treatment of Genitourinary Cancers, Barcelona, Spain, April 18, 2002
88. "New targets for therapy: Endothelin axis", Brains Trust Workshop, The Role of the Prostate in
Benign and Malignant Disease, Braselton, Georgia, May 19, 2002
18
89. "The Endothelin Axis and Prostate Cancer", 12th Annual Symposium on Cancer Research in
San Antonio, Keynote Speaker, San Antonio, Texas, July 12, 2002
90. "Update on Prostate Cancer", Jackson Hole Urology Conference, Jackson, Wyoming, August 2,
2002
91. "Reason to Hope: New Advances in the Treatment of Prostate Cancer", UPCI Public Awareness
Series, Pittsburgh, PA, September 19, 2002
92. "Endothelin and Prostate Cancer: Bench to Bedside", University of Virginia Cancer Center,
Charlottesville, Virginia, October 11, 2002
93. "Endothelin and Prostate Cancer", 4th Annual Weisbach Lecture in Prostate Oncology,
University of Michigan, Ann Arbor, Michigan, October 28, 2002
94. "Novel approaches to PET Imaging of Prostate Cancer", 9th Prouts Neck Meeting on Prostate
Cancer, Prouts Neck, Maine, November 10, 2002
95. "Endothelin Inhibition", Innovations and Challenges in Prostate Cancer, Cambridge,
Massachusetts, November 16, 2002
96. "Diseases of the Prostate: Prostatitis, Cancer, Clinical Utility of PSA", Update in Internal
Medicine: 2002, Pittsburgh, PA, November 21, 2002
97. "Atrasentan: Mechanism of Action and Data from Preclinical Studies", Atrasentan Urological
Oncology Advisory Board, McLean, Virginia, December 14, 2002
98. "For PSA Relapse More Than Two Years After Local Therapy I Would…", Second Annual
Opinion Leader Summit, Targeted Therapies in the Treatment of Genitourinary Cancers, St.
Thomas, U.S. Virgin Islands, January 16, 2003
99. "I Would Bet the Farm on Endothelin Receptor Antagonists", Second Annual Opinion Leader
Summit, Targeted Therapies in the Treatment of Genitourinary Cancers, St. Thomas, U.S. Virgin
Islands, January 18, 2003
100. Judge, Chief Residents' Debate Meeting, The New York Section, American Urological
Association, New York, New, York, February 5, 2003
101. "Endothelin and prostate cancer: Bench to Bedside", Los Angeles Urological Society, Los
Angeles, CA, March 4, 2003
102. "Point/Counterpoint: Controversial Aspects of Diagnosis and Management of Prostate
Cancer", Clinical Update in Geriatric Medicine, Pittsburgh, PA, April 10, 2003
103. "Prostate Cancer and Radical Prostatectomy", UPMC Shadyside Nursing Inservice, Pittsburgh,
19
PA, April 14, 2003
104. "Watchful Waiting in the Management of Prostate Cancer", US TOO Support Group,
Pittsburgh, PA, April 16, 2003.
105. "Problem Cases in Localized Prostate Cancer", American Urological Association Meeting,
Plenary Session, Panelist, Chicago, IL, April 30, 2003
106. "Targeting Endothelin Receptors in Prostate Cancer: Preclinical and Phase I Data with
Atrasentan", Prostate Cancer: Emerging Trends in Prevention and Management, A Pre-ASCO
Industry-Sponsored Symposium, Chicago, IL May 30, 2003.
107. "Atrasentan Mechanisms of Action, Pre-clinical and Early Date", Abbott Laboratories Advisory
Board, Bermuda, July 17, 2003.
108. "Endothelin Receptors as Therapeutic Targets in Prostate Cancer: Preclinical and Early Clinical
Data", 3rd International Prostate Cancer Congress, Bermuda, July 19, 2003.
109. "ET and Cancer Biology", First International Colloquium on Endothelin and Cancer",
conference Co-Chair, Chicago, IL, September 12, 2003.
110. "Prostate Cancer Overview", Shriner's Temple, Pittsburgh, PA, September 18, 2003.
111. "Oncological Management of Prostate Cancer after Surgery", Division of
Hematology/Oncology Grand Rounds, University of Pittsburgh School of Medicine, Pittsburgh,
PA, October 15, 2003.
112. "Update on Disease of the Prostate", Update in Internal Medicine 2003: Practical Approaches
to Common Medical Problems, Pittsburgh, PA, November 6, 2003.
113. "Update on Endothelin Inhibition", Innovations and Challenges in Prostate Cancer,
Cambridge, MA, November 8, 2003.
114. "Treatment of advanced, Hormone-Refractory, Metastatic Prostate Cancer with Atrasentan:
Phase III Clinical Trial Data", 10th Annual Scientific Retreat, CaP CURE, New York, NY,
November 9, 2003.
115. "Atrasentan in Metastatic Hormone Refractory Prostate Cancer", Chemotherapy Foundation
Symposium XXI, New York, New York, November 14, 2003.
116. "Phase 3 Trial of Endothelin Receptor Antagonist, Atrasentan, in Hormone Refractory Prostate
Cancer", Late-Breaking Developments, 4th Annual Urologic Oncology meeting, Bethesda,
Maryland, December 6, 2003.
117. "The role of selective endothelin receptor antagonists-atrasentan: rationale and mode of action;
preclinical evidence." New Persepctives in Prostate Cancer: The role of selective endothelin receptor
20
antagonists", Meeting Co-Chair, Miami, Florida, January 10, 2004.
118. "Post Radical Prostatectomy Cancer Management", Forty-Seventh Annual Winter Meeting,
Buffalo Urological Society, Buffalo, New York, January 15, 2004.
119. "Top Films Based on True Stories", ", Non-Medical Lecture, Forty-Seventh Annual Winter
Meeting, Buffalo Urological Society, Buffalo, New York, January 15, 2004.
120. "What's New in Prostate Cancer", 24th Annual Jackson Hole Urologic Conference, Jackson
Hole, Wyoming, February 6, 2004.
121. "Diagnosis and Treatment of Prostate Cancer", 2004 Joseph F. Mulach Medical Lecture, St.
Clair Hospital, Pittsburgh, Pennsylvania, February 18, 2004.
122. "Renal Cell Carcinoma: Looking to the future: Thrombospondin Mimetic", Third International
Symposium on Genitourinary Cancers, Santa Barbara, California, February 26, 2004.
123. "Prostate: State of the Science: Non-Chemotherapy/Non Hormonal Therapy", Third
International Symposium on Genitourinary Cancers, Santa Barbara, California, February 28, 2004.
124. "Hot Topics: Case Studies and Discussion with Panel of Experts on Controversial Topics in
Prostate Cancer Treatment", Contemporary Prostate Cancer Treatments, Pittsburgh, Pennsylvania,
March 12, 2004.
125. "Prostate Cancer Update", Fox Chapel Rotary Club, Pittsburgh, Pennsylvania, March 22, 2004.
126. "The Endothelin Axis in Prostate Cancer", Johns Hopkins Department of Urology Grand
Rounds, Baltimore, MD April 22, 2004.
127. "Prostate Cancer Management after Radical Prostatectomy", University of Wisconsin, Division
of Urology, Madison, Wisconsin, April 29, 2004.
128. "ETA Receptor Antagonist (Atrasentan): Current Status", Society of Urologic Oncology, San
Francisco, California, May 8, 2004
129. "Endothelin Receptor Antagonists", Fourth International Prostate Cancer Congress, Grand
Bahama Island, July 17, 2004
130. "When to refer patients", Hormone Refractory Prostate Cancer, Chicago, Illinois, September
18, 2004
131. "Clinical Cases in Prostate Cancer", UPMC Passavant Hospital Grand Rounds, Pittsburgh, PA,
September 21, 2004
132. "Hormone Refractory Prostate cancer 2004: Do We have Anything to Improve Survival and
Lessen Suffering?", 62nd Annual Meeting of the Mid-Atlantic Section of the AUA, Hyatt Regency
21
Chesapeake Bay, Cambridge, Maryland, October 6, 2004.
133. "Diagnosis and Treatment of Prostate Cancer" and "Endothelin Axis and Prostate Cancer",
Abbott Oncology Team Building Meeting, Chicago, Illinois, October 13, 2004.
134. "Novel Therapies in Hormone Refractory Prostate Cancer", 56th Annual Meeting of the
Northeastern Section, AUA, Savannah, Georgia, October 28, 2004.
135. "Competencies", Program Directors Meeting, 56th Annual Meeting of the Northeastern
Section, AUA, Savannah, Georgia, October 31, 2004.
136. "Targeting the Endothelin Axis", 10th Prouts Neck Meeting on Prostate Cancer, Prouts Neck,
Maine, November 7, 2004.
137. "Prostate Cancer Management after Radical Prostatectomy", US Too, Pittsburgh, Pennsylvania,
November 17, 2004.
138. "Xinlay (atrasentan): The Endothelin Axis and a Clinical Update in Hormone-Refractory
Prostate Cancer", SUO Advisory Board, Washington DC, December 4, 2004.
139. "Xinlay (atrasentan): Regional Advisory Board Meeting", Atlanta, Georgia, December 5, 2004.
140: "Atrasentan Data", 4th International Symposium on Genitourinary Cancers, Beverly Hills,
California, January 29, 2005.
141. "Beyond Curative Intent: Future Role of Primary Prostate Cancer Management", 15th
International Prostate Cancer Update, Vail, Colorado, February 11, 2005.
142. "Atrasentan for the Treatment of Advanced Prostate Cancer", 15th International Prostate
Cancer Update, Vail, Colorado, February 11, 2005.
143. "Pathophysiology of the Endothelin Axis in the Development and Progression of Prostate
Cancer", New Horizons in the Medical Treatment of Prostate Cancer, Orlando, Florida, February
18, 2005.
144. "Clinical Cases in Prostate Cancer", Clinical Science Managers Meeting, Abbott Laboratories,
Chicago, Illinois, March 21, 2005
145. "Endothelin Axis in Prostate Cancer: Bench to Bedside", Northwestern University Feinberg
School of Medicine, Department of Urology, Alumni Review Course, Breckenridge, Colorado, April
2, 2005
146. "ETA Antagonists in Prostate Cancer and the Relationship to Bone Metastasis", Fourth Annual
Skeletal Complications of Malignancy, Bethesda, Maryland, April 28, 2005
147. "Overview of Prostate Cancer Diagnosis and Treatment", Urology Nursing 2005, Pittsburgh,
22
Pennsylvania, May 12, 2005
VISITING PROFESSORSHIPS
1. Department of Urology, School of Medicine and Biomedical Sciences, University at Buffalo, The
State University of New York, Buffalo, New York, January 15, 2004
2. Division of Urology, University of Wisconsin Medical School, Madison, Wisconsin, April 29-30,
2004
BIBLIOGRAPHY
Peer Reviewed Publications
1. Bresticker, M.A., Nelson, J.B., Huang, C., Wolf, J., Anderson, B. Plasma Renin Activity in Renal
Transplant Patients with Hypertension. American Journal of Hypertension 4:623-626, 1991.
2. Maizels, M., Reisman, M., Flom, L.S., Nelson, J., Fernbach, S., Firlit, C., Conway, J. Grading
Nephroureteral Dilatation Detected in the First Year of Life: Correlation with Obstruction. Journal
of Urology 148:609-614, 1992.
3. Nelson, J.B., Bresticker, M.A., Nahrwold, D.L. Computed Tomography in the Initial Evaluation
of Patients with Blunt Trauma. Journal of Trauma 33:722-727, 1992.
4. Ignatoff, J., Nelson, J. Use of Extracorporeal Shock Wave Lithotripsy in a Solitary Kidney with
Renal Artery Aneurysm. Journal of Urology 149:359-360, 1993.
5. Nelson, J., Graham, J. Lithotripsy of Urinary Calculi by Tunable Pulsed Dye Lasers: A
Randomized In Vitro Study. Journal of Urology 151:656-659, 1994.
6. Nelson, J.B., Oyasu, R. and Dalton, D.P. The Clinical and Pathological Manifestations of Renal
Tumors in Von Hippel-Lindau Disease. Journal of Urology 152:2221-2226, 1994.
7. Graham, J.B. and Nelson, J.B. Percutaneous Caliceal Irrigation during Extracorporeal Shock
Wave Lithotripsy for Lower Pole Renal Calculi. Journal of Urology 152:2227, 1994.
8. Nelson, J.B., Blum, M.D. and Cook, W.A. Retroperitoneal Pulmonary Sequestration: A Rare
Congenital Anomaly in a 71-year-old Man. Journal of Urology 152:2341-2343, 1994.
9. Nelson, J.B., Hedican, S.P., George, D.J., Reddi, A.H., Piantadosi, S., Eisenberger, M.A. and
Simons, J.W. Identification of Endothelin-1 in the Pathophysiology of Metastatic Adenocarcinoma
of the Prostate. Nature Medicine 1:944-949, 1995.
10. Carducci, M.A., Nelson, J.B., Chan-Tack, K., Ayyagari, S.R., Sweatt, W., Campbell, P.S., Nelson,
W.G. and Simons, J.W. Phenylbutyrate induces Apoptosis in Human Prostate Cancer and is more
23
potent the Phenylacetate. Clinical Cancer Research 2:379-387, 1996.
11. Nelson, J.B., Chan-Tack, K., Hedican, S.P., Magnuson, S.R., Opgenorth, T.J., Bova, S.G. and
Simons, J.W. Endothelin-1 production and decreased ETB receptor expression in advanced prostate
cancer. Cancer Research 56:663-668, 1996.
12. Nelson, J.B., Lee, W-H,, Nguyen, S.H., Jarrard, D.F., Brooks, J.D., Magnuson, S.R., Opgenorth,
T.J., Nelson, W.G. and Bova, G.S. Methylation of the 5' CpG island of the endothelin B receptor
gene is common in human prostate cancer. Cancer Research 57:35-37, 1997.
13. Joseph, B.J.K., Nelson, J.B., Denmeade, S.R. and Isaacs, J.T. Androgens regulate vascular
endothelial growth factor content in normal and malignant prostatic tissue. Clinical Cancer Research
3:2507-2511, 1997.
14. Yoshida, B.A., Chekmareva, M.A., Wharam, J.F., Kadkhodaian, M., Stadler, W., Boyer, A.,
Watabe, K., Nelson, J.B. and Rinker-Schaeffer, C. W. Prostate cancer metastasis-suppressor genes: a
current perspective. In Vivo 12:49-58, 1998.
15. Jackman, S.V., Moore, R.M. and Nelson, J.B. Nephrogenic adenoma of the ureter: endoscopic
diagnosis and management. Urology 52:316-317, 1998.
16. Cadeddu, J.A., Ono, Y., Clayman, R.V., Barrett, P.H., Janetschek, G., McDougall, E.M., Moore,
R.G., Kinukawa, T., Elbahnasy, A.M., Nelson, J.B. and Kavoussi, L.R. Laparoscopic nephectomy
for renal cell cancer; evaluation of efficacy and safety: a multi-center experience. Urology 52:773777, 1998.
17. Sokoll, L.J., Partin, A.W., Nelson, J.B. and Chan, D.W. A Critical analysis of false elevations in
PSA results reported with the Abbott AxSYM assay. The Prostate 38:79-80, 1999.
18. Nelson, J.B., Opgenorth, T.J., Fleischer, L.A. and Frank, S.M. Perioperative Plasma Endothelin-1
and Big Endothelin-1 Concentrations in Patients at Risk for Morbid Cardiac Events. Anesthesia &
Analgesia 88:898-903, 1999.
19. Nelson, J.B., Nguyen, S.H., Wu-Wong, J.R., Opgenorth, T.J., Dixon, D.B., Chung, L.W.K., and
Inoue, N. New bone formation in an osteoblastic tumor model is increased by endothelin-1
overexpression and decreased by endothelin A receptor blockade. Urology 53:1063-1069,1999.
20. Carducci, M.A., DeWeese, T., Nelson, J.B. PSA and other biomarkers of the therapeutic
response. Urologic Clinics of North America 26:291-302, 1999.
21. Artemov, D., Pilatus, U., Chu, S., Mori, N., Nelson, J.B. and Bhujwalla, Z.M. Dynamics of
prostate cancer cell invasion studied in vitro by NMR microscopy. Magnetic Resonance in Medicine
42:277-282, 1999.
22. Pflug, B.R. Reiter, R.E. and Nelson, J.B. Caveolin expression is decreased following androgen
deprivation in human prostate cancer cell lines. Prostate 40:269-273, 1999.
24
23. Nelson, J.B. and Carducci, M.A. The role of the endothelin axis in prostate cancer. The Prostate
Journal 1:126-130,1999.
24. Nelson, J.B., Chen, R.N., Bishoff, J.T., Oh, W.K., Kantoff, P.W., Donehower, R.C. and
Kavoussi, L.R. Laparoscopic retroperitoneal lymph node dissection for clinical stage I
nonseminomatous germ cell testicular tumors. Urology 54:1064-1067, 1999.
25. Nelson, J.B. and Carducci, M.A. The Role of Small Bioactive Peptides and Cell Surface
Peptidases in Androgen Independent Prostate Cancer. Cancer Investigation 18:87-96, 2000.
26. Usmani, B.A., Shen R., Janeczko, M. Papandreou, C.N., Lee, W-H, Nelson, W.G., Nelson, J.B.
and Nanus, D.M. Methylation of the neutral endopeptidase promoter CpG island in human prostate
cancer. Clinical Cancer Research 6:1664-1670, 2000.
27. Han, M. and Nelson, J.B. Nonsteriod antiandrogens in prostate cancer-current treatment
practice. Expert Opinion on Pharmacology 1:443-449, 2000.
28. Pirtskahalaishvili, G. and Nelson, J.B. Endothelium-derived factors as paracrine mediators of
prostate cancer progression. The Prostate 44:77-87, 2000.
29. Roberts, W.W., Nelson, J.B., Fishman, E.K., and Jarrett, T.W. Diagnosis of retroperitoneal
pulmonary sequestration using computerized tomography guided fine needle biopsy. Journal of
Urology, 164:445, 2000.
30. Konety BR, Nguyen T-ST, Brenes G, Lewis N, Saul M, Nelson JB, and Getzenberg RH.
Evaluation of the effect of spinal cord injury (SCI) on serum PSA levels. Urology 56:82-86, 2000.
31. Pflug, B.R., Zheng, H., Udan, M.S., Marshall, F.F., Brooks, J.D. and Nelson, J.B. Endothelin
axis expression and function in renal cell carcinoma: survival through ETA receptor and frequent
methylation of EDNRB. Submitted, Cancer Clinical Research, 2003.
32. Ackerstaff, E., Pflug, B.R., Nelson, J.B., Bhujwalla Z. Detection of Increased Choline
1
Compounds with H NMR Spectroscopy following Malignant Transformation of Human Prostatic
Epithelial Cells. Cancer Research 61, 3599-3603, 2001.
33. Pizer, E.S., Pflug, B.R., Bova, G.S., Han, W.F., Udan, M.S., and Nelson, J.B. Increased fatty acid
synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate
47:102-110, 2001.
34. Konety B.R. and Nelson, J.B. Nonandrogenic mediators of prostatic growth.
Hematology/Oncology Clinics of North America 15:459-476, 2001.
35. Xia, W., Unger, P., Miller, L., Nelson, J., Gelman, I.H. The Src-suppressed C kinase substrate,
SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Research 61:5644-5651, 2001.
25
36. Carducci, M.A., Nelson, J.B., Bowling, M.K., Rogers, T., Eisenberger, M.A., Sinibaldi, V.,
Donehower, R., Leahy, T.W., Carr, R.A., Isaacson, J.D., Janus, T.J., Andre, A., Hoseman, B.S., and
Padley, R.J. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety
and pharmacokinetics. Journal of Clinical Oncology 20:2171-2180, 2002.
37. Kopetz, S., Nelson, J.B., Carducci, M.A. Endothelin-1 as a therapeutic target in prostate cancer.
Invest New Drugs 20:173-182, 2002.
38. Carducci, M.A., Padley, R.J., Breul, J., Vogelzang, N.J., Zonnenberg, B.A., Daliani, D.D.,
Schulman, C.C., Nabulsi, A.A., Humerickhouse, R.A., Weinberg, M.A., Schmitt, J.L. and Nelson,
J.B. The effect of endothelin-A receptor blockade with atrasentan on tumor progression in men
with hormone refractory prostate cancer: a randomized, placebo controlled trial. Journal of Clinical
Oncology, 21:679-689, 2003.
39. Nelson, J.B., Padley, R.J., Breul, J., Vogelzang, N.J., Zonnenberg, B.A., Daliani, D.D., Schulman,
C.D., Schmitt, J.L., Carducci, M.A. Suppression of prostate cancer-induced bone remodeling by the
endothelin receptor A antagonist atrasentan. Journal of Urology, 169:1143-1149, 2003.
40. Pirtskhalaishvili, G., and Nelson, J.B. The endothelin receptor: a novel target for anticancer
therapy. American Journal of Cancer 1:81-91, 2002.
41. DeMiguel F., Lee, S.O., Lou, W., Xiao, X., Pflug, B.R., Nelson, J.B., and Gao, A.C. Stat3
enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.
Prostate 52:123-129, 2002.
42. DePrimo, S.E., Nelson, J.B., Reiter, R.E., Matese, J., Fero, M., Tibshirani, R., Brown, P.O., and
Brooks, J.D. Transcriptional Programs Activated by Exposure of Human Prostate Cancer Cells to
Androgen. Genome Biology 3:32.1-32.12, 2002.
43. Krill, D., Wagner, T., Konetry, B., Dhir, R., Nelson, J., Becich, M. Predicting invasive prostate
cancer in men with radical prostatectomy based on comorbidity and nonsteroidal anti-inflammatory
drugs. Submitted, Journal of Urology, 2003.
44. Nelson, J.B., Bagnato, A., Battistini, B., Nisen, P. The endothelin axis: emerging role in cancer.
Nature Reviews Cancer 3:110-116, 2003.
45. Carroll, P.R., Benaron, D.A., Balckledge, G., Coakley, F.V., D'Amico, A.V., Higaon, C.S.,
Iverson, P., Kattan, M., Nanus, D.M., Nelson, J.B., Oh, W.K., Roach, M., Sellers, W.R., Smith, M.R.,
McMann, M.C., Kantoff, P.W.: Third International conference on Innovations and Challenges in
Prostate Cancer: Prevention, Detection and Treatment. Journal of Urology 170:S3-S5, 2003.
46. Nelson, J.B.: Endothelin inhibition: Novel therapy for prostate cancer. Journal of Urology
170:S65-S68, 2003.
26
47. Pflug, B.R., Pecher, S.M., Brink, A.W., Nelson, J.B., Foster, B.A.: Increased fatty acid synthase
expression and activity during progression of prostate cancer in the TRAMP model. Prostate 57:245254, 2003.
48. Nelson, J.B. and Lepor, H.B.: Prostate Cancer: Radical Prostatectomy. Urologic Clinics of North
America 30:703-723, 2003.
49. Chung, S.Y., Stein, R.J., Cannon, T.W., Nelson, J.B.: Novel technique in the management of low
flow priapism. Journal of Urology 170:1952, 2003.
50. Patel, A., Coates, P., Nelson, J.B., Trump, D., Resnick, N.M., Greenspan, S.L.: Does bone
density influence health-related behaviors of elderly men at risk for osteoporosis? Journal of Clinical
Densitometry 6:323-329, 2003.
51. Guruli, G., Pflug, B.R., Pecher, S., Makarenkova, V., Shurin, M.R., Nelson, J.B.: Human
dendritic cell maturation, function and survival are dependent on endothelin-1, endothelin A
receptor and endothelin B receptor autocrine loops. Blood 104:2107-2115, 2004.
52. Yu, Y.P., Landsittel, D., Jing, L., Nelson, J.B., Ren, B., Liu L., McDonald C., Thomas, R., Dhir,
R., Chandran, U., Gilbertson, J., Kinkelstein, Michalopoulos, G., Becich, M., and Luo, J-H.: Gene
expression alterations in prostate cancer predicting tumor aggression and preceding development of
malignancy. Journal of Clinical Oncology 22:2790-2799, 2004.
53. Davies, B.J., Chung, S.Y., and Nelson, J.B.: Delayed intraoperative hydration limits blood loss
during radical retropubic prostatectomy. Urology 64:712-716, 2004.
54. Stein, R.J., Santos, S., Nagatomi, J., Minnery, B.S., Xavier, M., Patel, A.S., Nelson, J.B., Futrell,
W.J., Yoshimura, N.,Chancellor, M.B., DeMiguel, F.: A new sensation: "cool" and "hot" receptors in
the bladder and lower genitourinary tract. Journal of Urology 172:1175-1178, 2004.
55. Ogawa, T., Kamo, I., Pflug, B.R., Nelson, J.B., Igawa, Y., Nishizawa, O., de Groat, W.C.,
Chancellor, M.B., Yoshimura, N.: Differential roles of peripheral and spinal endothelin receptors in
the micturition reflex in rats. Journal of Urology 174:1533-1537, 2004.
56. Pecher, S., Pflug B.R., Brink, A.K.W., Nelson, J.B.: Endothelin A receptor blockade does not
alter PSA secretion in prostate cancer cell lines. The Prostate 60:175-177, 2004.
57. Bennett, N.E., Kim, J,H,m Sasaki, K., Yoshimura, N., Wolfe, D.P., Goins, W.F., Nelson, J.B., de
Groat, W.C., Glorioso, J.C., Chancellor, M.B.: Improvement of erectile dysfunction after neutrophic
factor gene therapy in diabetic rats. Journal of Urology 173:1820-1824, 2005.
58. Carducci, M.A., Nelson, J.B., Saad, F., Abrahamsson, P-A., Dearnaley, D., Schulman, C.C.,
Isaacson, J.D., Rountree, L.V., Humerickhouse, R.A., Allen, A.R., Nisen, P.D.: A phase 3 trial of the
selective endothelin receptor antagonist, atrasentan, in men with metastatic, hormone-refractory
prostate cancer. Submitted, Journal of Clinical Oncology, 2004.
27
59. Xiao, D., Zeng, Y., Choi, S.A., Nelson, J.B. and Singh, S.V.: Caspase dependent apopotosis
induction by phenethyl isothiocyanate, a cruciferous vegetable derived cancer chemopreventive
agent, is mediated by Bak and Bax. Clinical Cancer Research 11:2670-2679, 2005.
60. Nelson, JB. Endothelin receptor antagonists. Submitted, World Journal of Urology, 2004.
61. Yu, Y.P., Paranjpe, S., Nelson, J.B., Finkelstein, S., Ren, B., Michalopoulos, G., and Luo, J-H.
High throughput Screening of Methylation Status of Genes in Prostate Cancer Using
Oligonucleotide Methylation Array. Carcinogenesis 26:471-479, 2005.
62. Cannon, G., Nelson, J.B. Perineural Invasion in Prostate Cancer Biopsies is Not Associated With
Higher Rates of Positive Surgical Margins. Accepted, The Prostate, 2004.
63. Carroll, P.R., Chan, M.L. D'Amico A.V., Gelmann, E.P., Iversen, P., Klotz L., Nelson, J.B.,
Nelson, P.S., Nelson, W.G., Oh, W.K., Rosen, N., Rubin, M.A., Sandler, H., Sellers, W.R., Smith,
M.R., Xu, J., McMann, M.C., Kantoff, P.W.: Fourth international conference on innovations and
challenges in prostate cancer: prevention, detection and treatment. Journal of Urology 172:S3-S5,
2004.
64. Carducci, M.A., Carroll, P.R., DiPaola, R.S., Nelson, J.B., Petrylak, D.P., Smith, M.A.,
Thompson, I.M. Hormone-refractory prostate cancer: issues, approaches, and recommendations.
Urology 65: Supplement 5A, 1-2, 2005.
64. Smith, M.R. and Nelson, J.B.: Future therapies in hormone-refractory prostate cancer. Urology
65: Supplement 5A, 9-17, 2005.
65. Godara, G., Cannon, G.W., Cannon, G.M., Bies, R,R,m Nelson, J.B. and Pflug, B.R.: Role of
endothelin axis in progression to aggressive phenotype of prostate andenocarcinoma. Accepted, The
Prostate, 2004.
66. Nelson, J.B., Udan. M.S., Guruli, G. and Pflug, B.R.: Endothelin-1 inhibits apoptosis in prostate
cancer. Accepted, Neoplasia, 2005.
67. Ben-David, B., Swanson, J., Chelly, J.E. and Nelson, J.B.: Bilateral paravertebral blocks for
radical prostatectomy provides better analgesia and shortens hospital stay. Submitted, Urology, 2005.
Non-Peer Reviewed Publications
1. Nelson, J.B., and Carducci, M.A. The role of endothelin-1 and endothelin receptor antagonists in
prostate cancer. The British Journal of Urology, International 85 Suppl. 2: 45-48, 2000.
2. Nelson, J.B. What’s new in prostate cancer. Campbell’s Urology: Update Series, 2000.
3. Nelson, J.B. Prostate Disease. Clinical Geriatrics 8:60-66, 2000.
28
4. Nelson, J.B. Endothelin receptor antagonists and advanced prostate cancer. www.urohealth.org,
published on-line, 2001.
5. Pirtskhalaishvili, G., Hrebinko, R.L. and Nelson, J.B. The treatment of prostate cancer: an
overview of current options. Cancer Practice 9:295-306, 2001.
6. Nelson, J.B.: Targeting the Endothelin Axis in Prostate Cancer. Cancer Conference Highlights
7:3-5, 2003.
7. Nelson, J.B.: Atrasentan: Endothelin-1 Receptor Antagonist in Prostate Cancer. AUA News 8:2731, 2003.
8. Nelson, J.B.: Role of the Endothelin Pathway in the Pathophysiology of Prostate Cancer.
Advances in Prostate Cancer, accepted for publication, 2003.
9. Nelson, JB, Allen, A., Hultling, S., et al: Prediction of survival and time to progression using PSA
doubling time (PSADT) in men with HRPC. American Journal of Urology Review, 2 Supplement
8:6-7, 2004.
Letters
1. Nelson, J.B., Wather, M. and Kavoussi, L.R. Letter to Editor RE: A case of Cushing’s syndrome
due to adrenocortical carcinoma with recurrence 19 months after laparoscopic adrenalectomy.
Journal of Urology 159:1310, 1998.
Editorials
1. Nelson, J.B. Editorial Comment RE: Cytokine levels in the cystic masses associated with renal
cell carcinoma. Journal of Urology 159:1464, 1998.
2. Nelson, J.B. Alternatives to Death: Understanding Androgen Independent Prostate Cancer.
Nature Medicine, 4:1011-1012, 1998.
3. Nelson, J.B. Book Review: New Perspectives in Prostate Cancer (Belldegrun, A., Kirby, R.S. and Oliver
R.T.D., eds.), Isis Medical Media, 1998. New England Journal of Medicine 340:158, 1999.
4. Nelson, J.B. Endothelin receptor antagonists in the treatment of prostate cancer. The Prostate
49:91-92, 2001.
5. Nelson, J.B. Is brachytherapy a kinder, gentler treatment for prostate cancer? Journal of Urology
171:1109-1110, 2004.
6. Nelson, J.B. Book Review: 3rd International Consultation on Prostate Cancer - Paris (Denis, L., Bartsch,
G., Khoury, S., Murai, M., and Partin, A., eds), Health Publications, 2003. Urology 64:1269, 2004.
29
7. Nelson, J.B. Eliminating the Current Bell Curve to Improve the Results of Radical
Prostatectomy. Journal of Urology 173:1848-1849, 2005.
BOOK CHAPTERS
1. Nelson, J.B. and Marshall, F.F. Surgical Treatment of Locally Advanced Renal Cell Carcinoma. In
Comprehensive Textbook of Genitourinary Oncology, pp. 218-236, (Vogelzang, N.J., Shipley, W.U.,
Scardino, P.T., and Coffey, D.S., Eds.) Baltimore: Williams and Wilkins, 1996.
2. Nelson, J.B. and Marshall, F.F. Renal Cell Carcinoma: Management and Prognosis. In Urologic
Oncology, pp. 174-194, (Oesterling, J.E. and Richie, J.P., Eds.) Philadephia: W.B. Saunders, 1997.
3. Nelson, J.B. Prostate Disease. In Geriatrics Review Syllabus, pp. 291-294, (Cobbs, E.L., Duthie,
E.H., Murphy, J.B., Eds.) New York: The American Geriatrics Society, 1999.
4. Nelson, J.B. and Marshall, F.F. Surgical Treatment of Locally Advanced Renal Cell Carcinoma. In
Comprehensive Textbook of Genitourinary Oncology, Second Edition, pp. 183-201, (Vogelzang,
N.J., Shipley, W.U., Scardino, P.T., and Coffey, D.S., Eds.) Baltimore: Lippincott Williams and
Wilkins, 2000.
5. Walsh, P.C. and Nelson, J.B. Prostate Cancer: Natural History. In Objectives for Urology
Residency Education 5th Edition, pp. 294-295, (Wein, A.J., Ed.), 2001.
6. Walsh, P.C. and Nelson, J.B. Radical Retropubic Prostatectomy. In Objectives for Urology
Residency Education 5th Edition, pp. 298-302 (Wein, A.J., Ed.), 2001.
7. Nelson, J.B. Endothelin Receptor Antagonist ABT-627 for Prostate Cancer. In 2nd International
Consultation on Prostate Cancer, pp. 84-86, (Murphy, G., Khoury, S., Partin, A., Denis, L., Ed.).
Plymouth, UK: Plymbridge Distributors Ltd., 1999.
8. Nelson, J.B. The Role of Small Bioactive Peptides and Cell Surface Peptidases in Androgen
Independent Prostate Cancer. In Prostate Cancer: Biology, Genetics and the New Therapeutics, pp.
433-447, (Chung, L.W.K., Isaacs, W.B., Simons J.W., Eds.) Totowa, New Jersey: Humana Press,
2001.
9. Pirtskahalaishvili, G. and Nelson, J.B.: Endothelins. In Wiley Encyclopedia of Molecular Medicine,
John Wiley & Sons, Inc., 2002. DOI: 10.1002/0471203076.emm0489 Article Online Posting Date:
January 15, 2002.
10. Kibel, A.S. and Nelson, J.B.: Molecular Genetics and Cancer Biology. In Campbell's Urology, 8th
Edition, pp. 2625-2671, (Walsh P.C., Retik A.B., Vaughan E.D., Wein A.J., Eds.) Philadelphia,
Pennsylvania, Saunders, 2002.
11. Carducci, M.A. and Nelson, J.B.: Management of Bone Metastases in Patients With Prostate
Cancer. In Prostate Cancer Foundation’s Report to the Nation on Prostate Cancer 2004, Medscape
30
Hematology-Oncology, publication pending.
SELECTED ABSTRACTS
1. Nelson, J., Bresticker, M., Huang, C., Wolf, J. Relationship of Proteinuria to Renin as a
Prognosticator of Graft Loss in Hypertensive Renal Allograft Recipients. American Journal of
Hypertension 3:68A, 1990. (ABSTRACT)
2. Bresticker, M., Nelson, J., Huang, C., Wolf, J. Plasma Renin Activity in Renal Transplant Patients
with Hypertension. American Journal of Hypertension 3:68A, 1990 (ABSTRACT).
3. Nelson, J., Grapey, D., Cheng, E., Gradishar, W., Kozlowski, J. Primary Retroperitoneal
Teratoma: A Rare Cause of Secondary Hyperaldosteronism and Sustained Hypertension. Presented
at the 65th Annual Meeting of the North Central Section of the American Urological Association,
Scottsdale, Arizona, November 3-9, 1991.
4. Nelson, J., Oyasu, R., Dalton, D. Surgical Management of Renal Cell Carcinoma in von HippelLindau Syndrome: ? Bilateral Nephrectomy or Nephron Sparing Surgery. Presented at the 66th
Annual Meeting of the North Central Section of the American Urological Association, Dorado,
Puerto Rico, October 25-31, 1992.
5. Nelson, J., Graham, J. Effect of Pulsed Dye Laser Lithotripsy on Urinary Stones of Varying
Composition: A Randomized In Vitro Study. Presented at the 66th Annual Meeting of the North
Central Section of the American Urological Association, Dorado, Puerto Rico, October 25-31, 1992.
6. Ignatoff, J., Nelson, J. Use of Extracorporeal Shock Wave Lithotripsy in a Solitary Kidney with
Renal Artery Aneurysm. Presented at the 66th Annual Meeting of the North Central Section of the
American Urological Association, Dorado, Puerto Rico, October 25-31, 1992.
7. Nelson, J., Sutkowski, D., Sherwood, E., Kerr, H., Lee, C., Kozlowski, J. Nephrogenic Hepatic
Dysfunction (Stauffer's) Syndrome: Possible Etiologic Role of IL-6 and IL-8. Presented at the 46th
Annual Meeting of the Society of Surgical Oncology, Los Angeles, California, March 18-21, 1993.
8. Nelson, J.B., Sutkowski D.M., Sherwood E.R., Kerr, H.N., Lee, C., Kozlowski J.M. Etiologic
Role of Interleukins 6 and 8 in Nephrogenic Hepatic Dysfunction (Stauffer's) Syndrome. Journal of
Urology, 149:461A, 1993 (ABSTRACT).
9. Nelson, J.B., Sutkowski, D.M. and Kozlowski, J.M.: Role of Interleukins 6 and 8 in the in the
Production of Nephrogenic Hepatic Dysfunction. Proceedings of the American Association of
Cancer Research, 34:58, 1993 (ABSTRACT).
10. Nelson, J.B., Sutkowski, D.M., and Kozlowski, J.M. Association of Interleukin (IL) 6 and
Granulocyte Colony Stimulating Factor (G-CSF) to Nephrogenic Hepatic Dysfunction (Stauffer's)
Syndrome (SS). Presented at the 67th Annual Meeting of the North Central Section of the
American Urological Association, Milwaukee, WI, September 28-October 2, 1993.
31
11. Nelson, J.B., Riden, D.J., Sutkowski, D.M., and Kozlowski, J.M. The Enhanced Secretion of
Cytokines by Renal Cell Carcinoma: The In Vitro Effects of Interleukin 1 Alpha and Interleukin 2.
Presented at the 67th Annual Meeting of the North Central Section of the American Urological
Association, Milwaukee, WI, September 28-October 2, 1993.
12. Nelson, J.B., Sutkowski, D.M., Kozlowski, J.M. Association of interleukin 6 (IL-6) and
granulocyte colony stimulating factor (G-CSF) to nephrogenic hepatic dysfunction (Stauffer’s)
syndrome. Journal of Urology 151:484A, 1994 (ABSTRACT).
13. Nelson, J.B., Hedican, S.P., Ayyagari, S.R., Simons, J.W. Endothelin: a mitogen produced by
prostate cancer under androgenic and cytokine regulation circulates in advanced prostate cancer
patients. Proceedings of the American Association of Cancer Research, 36:38, 1995 (ABSTRACT).
14. Nelson, J.B., Hedican, S.P., Ayyagari, S.R., Simons, J.W. Endothelin: a mitogenic product of
human prostate cancer under androgenic and cytokine regulation is detected in advanced prostate
cancer patients. Proceedings of the American Urological Association, 153:283A, 1995
(ABSTRACT).
15. Lee, W.-H., Bova, G.S., Jarrard, D.F., Brooks, J.D., Nelson W.G., Simons J.W., Nelson, J.B.
Methylation of the endothelin B receptor gene in human prostate cancer. Proceedings of the
American Association of Cancer Research, 37:245, 1996 (ABSTRACT).
16. Nelson, J.B., Chan-Tack, K., Hedican, S.P., Bova, G.S., Simons, J.W., Magnuson, S.R.,
Opgenorth, T.J. Endothelin-1 production and ETA receptor mediated proliferation accompanies
decreased ETB receptor expression in advanced prostate cancer. Presented at the 30th Annual
Scientific Meeting of the European Society for Clinical Investigation, Interlaken, Switzerland, April
24-27, 1996.
17. O’Hara, M.S., Veltri, R.W., Skirpstunas, P, Hedican, S.P., Partin, A.W., Nelson, J.B., Subong,
E.N., Walsh P.C. Basal PSA mRNA levels detected by quantitative reverse transcriptase
polymerase chain reaction (Q-RT-PCR-PSA) in blood from subjects without prostate cancer.
Proceedings of the American Urological Association, 155:418A, 1996 (ABSTRACT).
18. Nelson, J.B., Chan-Tack, K., Hedican, S.P., Bova, G.S., Simons, J.W. Endothelin-1 is expressed
in advanced prostate cancer: ETA receptor mediated proliferation accompanies decreased ETB
receptor expression. Proceedings of the American Urological Association, 155:602A, 1996
(ABSTRACT).
19. Hedican, S.P., Nelson, J.B., Bartkowski, L.M., Simons, J.W. Urokinase gene expression as a
biomarker of invasive human prostate cancer and target for therapy. Proceedings of the American
Urological Association, 155:602A, 1996 (ABSTRACT).
20. Nelson, J.B., Nguyen, S.H., Inoue, N., Carducci, M.A., Simons, J.W., Reddi, A.H. Endothelin-1
increases new bone formation in an osteoblastic tumor model. Presented at the NIDDK 7th Prouts
Neck Meeting on Prostate Cancer, October 16-20, 1996.
32
21. David-Beabes, G.L., Yang, E., Chamness, S.L., Burnett, A.L., Brooks, J.D., Nelson, J.B. Nitric
oxide production by human prostate cancer cell lines. Journal of Urology 157:23, 1997
(ABSTRACT).
22. Nelson, J.B., Lee, W.-H., Nguyen, S.H., Jarrard, D.S., Brooks, J.D., Bova, G.S., Nelson, W.G.
Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate
cancer. Journal of Urology 157:23, 1997 (ABSTRACT).
23. Nelson, J.B., Nguyen, S.H., Inoue, N. Endothelin-1 increases new bone formation in an
osteoblastic tumor model. Journal of Urology 157:24, 1997 (ABSTRACT).
24. Joseph, I.B.J.K., Nelson, J.B., Denmeade, S.R., Isaacs, J.T. Androgen regulation of vascular
endothelial growth factor in normal and malignant prostatic tissues. Presented at the Schilling
Research Conference, Santa Cruz, California, September, 18-21, 1997.
25. Nelson, J.B., Nguyen, S.H., Zheng, H., Ewing, C.M., Isaacs, W.B. A frameshift mutation of the
endothelin B receptor gene (EDNRB) in the prostate cancer cell line LNCaP. Proceedings of the
American Association for Cancer Research 39: 621, 1998 (ABSTRACT).
26. Nelson, J.B., Nguyen, S.H., Zheng, H., Ewing, C.M., Nelson, W.G., Isaacs, W.B. A frameshift
mutation of the endothelin B receptor gene (EDNRB) in the prostate cancer cell line LNCaP.
Journal of Urology 159:10, 1998 (ABSTRACT).
27. Cadeddu, J.A., Moore, R.G., Nelson, J.B., Kavoussi, L.R. Clayman, R.V., McDougall, E.M.,
Elbahnasy, A.M., Ono, Y., Kinukawa, T., Barrett, P.H., Janetschek, G. Laparoscopic nephrectomy
for renal cell carcinoma: a multi-center evaluation of efficacy. Journal of Urology 159:147, 1998
(ABSTRACT).
28. Hedican, S.P., Nelson, J.B., Marshke, P., Carter, H.B., Walsh, P.C., Partin, A.W., Luo, G., Veltri,
R.W., O’Hara, S.M. Evaluation of preoperative prostate cancer staging and postoperative detection
of recurrence utilizing the reverse transcriptase polymerase chain reaction (RT-PCR). Journal of
Urology 159:289, 1998 (ABSTRACT).
29. Moses, M.A., Wiederschain, D., Loughlin, K.R., Zurakowski, D., Lamb, C.C., Nelson, J.B.,
Freeman, M.R. Urinary MMPs are multivariant predictors of disease status for human cancer.
Presented at the New York Academy of Science Meeting, “Inhibition of MMPs: Therapeutic
Implications,” October 21-24, 1998.
30. Pflug, B.R., Nelson, J.B. Caveolin expression is decreased in androgen independent clones of
LNCaP. Presented at the 8th Annual Meeting for the Society of Basic Urological Research, Prouts
Neck, Maine, November 12-15, 1998.
31. Nelson, J.B., Udan, M.S., Sokoll, L.J., Carducci, M.A. Endothelin A receptor blockade reduces
PSA levels in vivo (men with advanced prostate cancer) but not in vitro. Presented at the 8th Annual
Meeting for the Society of Basic Urological Research, Prouts Neck, Maine, November 12-15, 1998.
33
32. Pflug, B.R., Nelson, J.B. Caveolin expression is decreased in androgen independent clones of
LNCaP. Presented at New Research Approaches in the Prevention and Cure of Prostate Cancer,
AACR, Indian Wells, California, December 2-6, 1998.
33. Carducci, M.A., Bowling, M.K., Rogers, T., Leahy, T.L., Janus, T.J., Padley, R.J., Nelson, J.B.
Endothelin-receptor antagonist, ABT-627, for prostate cancer: initial trial results. Presented at New
Research Approaches in the Prevention and Cure of Prostate Cancer, AACR, Indian Wells,
California, December 2-6, 1998.
34. Nelson, J.B. Endothelins. The 1998 International Symposium on Biology of Prostate Growth.
Prostate 38: 257-258, 1999 (ABSTRACT).
35. Janus, J.T., Samara, E., Lanni, C., Zonnenberg, B., Carducci, M., Nelson, J. and Padley R.J. ABT627, endothelin-receptor antagonist, for advanced prostate cancer: Phase I pharamokinetic results.
Proceedings of the American Association for Cancer Research 40:91, 1999.
36. Carducci, M.A., Bowling, M.K. , Rogers, T., Janus, T.J., Padley, R.J. and Nelson, J.B. Phase I
clinical results of ABT-627, an endothelin receptor antagonist, for refractory adenocarcinoma.
Proceedings of the American Association for Cancer Research 40:91, 1999.
37. Carducci, M.A., Bowling K., Rogers, T., Leahy, T.L., Nelson, J.B., Janus, T.J., Padley, R.J.
Endothelin receptor antagonist, ABT-627, for prostate cancer: initial trial results. The Journal of
Urology 161:176, 1999.
38. Zheng, H., Pflug, B.R., Marshall, F.F., Nelson, J.B., Brooks, J.D. Frequent promoter methylation
of the endothelin B receptor gene EDNRB in human renal tumors. The Journal of Urology 161:137,
1999.
39. Thevarajah, S., Udan, M.S., Zheng, H., Pflug, B.R., Nelson, J.B. Endothelin axis expression in
renal cell carcinoma. The Journal of Urology 161:137, 1999.
40. Kavoussi, L.R., Nelson, J.B., Chen, R.N., Bishoff, J.T., Donehower, R.C., Oh, W.K., Kantoff,
P.W. Laparoscopic retroperitoneal lymph node dissection (RPLND) for clinical stage I
nonseminomatous germ cell testicular tumors (NSGCT). The Journal of Urology 161:5, 1999.
41. Koeneman, K.S., Yeung, F., Sikes, R.A., Chung, L.W.K., Nelson, J.B. Transcriptional
downregulation of PSA, and enhanced growth of prostate cancer (CaP) cells by co-culture with
osteoblastic cells. The Journal of Urology 161:99, 1999.
42. Chan, D.Y., Jarrett, T.W., Kavoussi, L.R., Nelson, J.B. Nanobacteria: possible association with
renal calculi. The Journal of Urology 161:249, 1999.
43. Carducci, M., Bowling, T., Rogers, T., Leahy, T., Moyse, D., Janus, R., Padley, R., Nelson, J.
ABT-627, and endothelin-receptor antagonist for refractory adenocarcinomas: Phase I and
pharmacologic evaluation. Proceeding of ASCO 18:162a, 1999.
34
45. Udan, M.S., Pflug, B.R., Nelson J.B. Endothelin-1 promotes survival of prostate cancer cells
through activation of AKT. Journal of Urology 163:31, 2000.
46. Pflug, B.R., Udan, M.S., Zheng, H., Nelson, J.B. Endothelin-1 inhibits paclitaxel-induced
apoptosis in renal cell carcinoma through Akt activation. Journal of Urology 163:112, 2000.
47. Kavoussi, L.R., Nelson, J.B., Bishoff, J.T., Kantoff, P.W., Donehower, R.C., Oh, W.K.
Laparoscopic retorperitoneal lymph node dissection for clinical stage 1 nonseminomatous germ cell
testicular tumors. Journal of Urology 163:131, 2000.
48. Nelson, J.B., Carducci, M.A., Dwason, M., Hippensteel, R.L., Padley, R.J., Janus, T.J. Preliminary
phase II results using ABT-627, and endothelin-a selective receptor antagonist, in men with
symptomatic hormone refractory prostate cancer. Journal of Urology 163:159, 2000.
49. Chan, D.Y., Jarrett, T.W., Kavoussi, L.R., Nelson, J.B. Nanobacteria: possible role in human
renal calculi. Journal of Urology 163:233, 2000.
50. Pflug, B.R., Udan, M.S., Nelson, J.B. Induction of apoptosis through endothelin B receptor in
prostate cancer cells. Proceedings of the American Association for Cancer Research 42:595, 2001.
51. DeMiguel, F., Pflug, B., Nelson, J.B., Gao, A.C. Stat3 activation and androgen-independent
progression of prostate cancer. Proceedings of the American Association for Cancer Research
42:702, 2001.
52. Pflug, B.R, Nelson, J.B. ,Udan, M.S. Endothelin-B receptor mediates apoptosis in prostate
cancer cells. Journal of Urology 165:50, 2001.
53. Microarray analysis of the transcriptional programs activated by exposure of prostate cancer cells
to androgen. Journal of Urology 165:142, 2001.
54. Nelson, J.B., Carducci, M.A., Zonnenberg, B., Breul, J., Padley, R.J., Janus, T. The endothelin-a
receptor antagonist atrasentan improves time to clinical progression in hormone refractory prostate
cancer: a randomized, double-blind, multi-national study. Journal of Urology 165:168, 2001.
55. Nelson, J.B., Carducci, M.A., Padley, R.J., Janus, T., Humerickhouse, R., Hippensteel, R. The
endothelin-A receptor antagonist atrasentan (ABT-627) reduces skeletal remodeling activity in men
with advanced, hormone refractory prostate cancer. Proceedings of ASCO 20:4a, 2001.
56. Carducci, M.A., Nelson, J.B., Padley, R.J., Janus, T, Hippensteel, R. The endothelin-A receptor
antagonist atrasentan (ABT-627) delays clinical progression in hormone refractory prostate cancer: a
multinational, randomized, double-blind, placebo-controlled trial. Proceedings of ASCO 20:174a,
2001.
57. Carducci, M.A., Nelson, J.B., Humerickhouse, R., Weinberg, M., Schmitt, A., Nabulsi, A. Effects
of atrasentan on progression and survival in men with hormone refractory prostate cancer: follow35
up to study M96-594. Proceedings of ASCO 21:178a, 2002.
58. Schulman C., Nelson, J.B., Weinberg, M., Humerickhouse, R.A., Schmitt, J.L., Nabulsi, A.A.
Atrasentan delayed PSA progression in a phase II trial of men with hormone refractory prostate
cancer. Journal of Urology 167:176, 2002.
59. Kim, J.H., Sasaki, K., Yoshimura, N, Goins, W.F., Glorioso, J.C., Nelson, J.B., Degroat, W.C.,
Chancellor, M.B. Herpes simplex virus mediated gene therapy for neurogenic erectile dysfunction:
proof of concept for afferent and efferent neuron transfection. Journal of Urology 167:234, 2002.
60. Pound, C.R., Patel, A.A., Dhir, R., Bastacky, S.I., Mu, X.C., Becich, M.J., Nelson, J.B.
Preservation of the neurovascular bundles (NVB) at radical prostatectomy (RRP) in men with
biopsy perineural invasion (PNI). Journal of Urology 167:337, 2002.
61. Pirtskhalaishvili, G., Mathis, C., Arlotti, J.A., Pflug, B.R., Nelson, J.B. PET imaging of prostate
cancer through manipulation of fatty acid synthase. Journal of Urology 167:362, 2002.
62. Pflug, B.R., Pecher, S., Brink, A.K., Nelson, J.B. Dysregulation of the fatty acid metabolic
pathway in the progression of prostate cancer. Proceedings of the American Association for Cancer
Research 44:80, 2003.
63. Pirtskhalaishvili, G., Pflug, B.R., Pecher, S., Makarenkova, V., Shurin, M., Nelson, J.B. Presence
of an endothelin-1/ETA autocrine loop in the maturation, differentiation and survival of human
dendritic cells. Proceedings of the American Association for Cancer Research 44:645, 2003.
64. Nelson, J.B., Isaacson, J.D., Eliopoulos, H.B., Allen, A.R. Relationship between time to PSA
progression and time to disease progression in patients with hormone-refractory prostate cancer
(HRPC). Proceedings of ASCO 22:409, 2003.
65. Humerickhouse, R., Nelson, J.B., Carducci, M.A., Nisen, P.D. Design and implementation of a
composite time to progression endpoint for phase III studies of atrasentan in prostate cancer.
Proceedings of ASCO 22:429, 2003.
66. Kim, J.H., Bennett, N.E., Seki, S., Yoshimura, N., Nelson, J.B., Morris, S., Chancellor, M.
Arginase inhibitor affects the urogenital system through manipulation of the nitric oxide (NO)
pathway. Journal of Urology 169:45, 2003.
67. Kim, J.H., Bennett, N.E., Sasaki, K., Yoshimura, N., Wolfe, D.P., Goins, W.F., Nelson, J.B., De
Groat, W.C., Glorioso, J., Chancellor, M.B. Neurotrophic factor gene therapy: potential cure for
post radical prostatectomy erectile dysfunction. Journal of Urology 169:303, 2003.
68. Bennett, N.E., Kim, J.H., Yoshimura, N, Wolfe, D., Groins W.F., Nelson, J.B., Glorioso, J.C.,
De Groat, W.C., Chancellor, M.B. Dramatic improvement of erectile dysfunction after neurotrophic
factor gene therapy in diabetic rats. Journal of Urology 169:304, 2003.
69. Kim, J.H., Bennett, N.E., Yoshimura, N., Chermansky, C., Kwon, D.D., Tarin, T., Nelson, J.B.,
36
De Groat, W.C., Qu-Peterson, Z., Huard, J., Chancellor, M.B. Neurorecovery and improved erectile
function using muscle derived stem cells (MDSC) in a model of post-radical prostatectomy erectile
dysfunction. Journal of Urology 169:323, 2003.
70. Cannon, G.M., Pound, C.R., Urda, S.J., Pirtskhalaishvili, G., Becich, M.J., Batasky, S.I., Dhir, R,
Mu, X.C., Nelson, J.B. Preservation of the neurovascular bundles (NVB) at radical prostatectomy
(RRP) in men with biopsy perineural invasion (PNI). Journal of Urology 169:441, 2003.
37